News Updates
More Articles
- WHO, Korea to build biomanufacturing training hub
- UK grants funding to Pictura Bio for AI-guided testing
- EMA committee proposes retraction of SCD drug's approval
- J&J seeks EMA approval of cilta-cel as second-line drug
- Moderna registers unit in China in search of opportunities
Novartis to offload some assets from ophthalmology portfolio
Novartis is considering the sale of some ophthalmology assets to focus on other growth areas, according to unnamed sources familiar with the matter. Assets that may be put up for sale include Xiidra, or lifitegrast ophthalmic solution, and Beovu, or brolucizumab-dbll. BioSpace (San Francisco) (3/14)
Read full article now.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!